Skip to content

Aggressive antihypertensive treatment for protecting cardiovascular complications in pre-diabetic hypertensive patients

Aggressive antihypertensive treatment for protecting cardiovascular complications in pre-diabetic hypertensive patients - APPROACH trial

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
JPRN
Registry ID
JPRN-UMIN000005541
Enrollment
60
Registered
2011-05-02
Start date
2009-11-01
Completion date
Unknown
Last updated
2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

1.Hypertensive patients with diabetes mellitus (DM), pre-diabetes: DM was defined as at least one of the following criteria: fasting blood glucose &gt

Interventions

Sponsors

Jichi Medical University School of Medicine
Lead Sponsor
International University of Health and Welfare Hospital
Collaborator

Eligibility

Sex/Gender
All

Inclusion criteria

Inclusion criteria: 1. Hypertension with dibetes mellitus or pre-diabetes. 2. Morning systolic blood pressure >=135 with self-monitoring BP at home 3. The age >=30 years 4. The patients were either never treated, single drug therapy (CCB or ACE-I, ARB), or double drug therapy in combination with CCB plus ACE-I, ARB.

Exclusion criteria

Exclusion criteria: 1. Secondary hypertension 2. Patients with congestive heart failure, acute MI less than 6months, acute stroke less than 6months, atrial fibrilation, AV block, or significant arrhythmia. 3.Hepatic damage (AST, ALT >twice of upper limits, renal dysfunction (serum creatine 4. Allergy, or allergic reaction 5. Dementia from whom we cannot obtain informed consent. 6. pregnancy 7. for whom the attending doctor considerd he or she is not appropriate for the study.

Design outcomes

Primary

MeasureTime frame
BP control rate: the percentage of attaining target home BP <125/75mmHg

Secondary

MeasureTime frame
BP: BP control rate and the degree of BP lowering at the end of the treatment Renal function: the changing rate of serum creatinine (eGFR) and urinary microalbumin Diabetes: changing rate of HbA1c and fasting blood glucose Pulse wave velocity (PWV) Augmentation index at radial artery Baroreflex sensitivity (BRS) Flow mediated dilatation (FMD)

Countries

Japan

Contacts

Public ContactKazuo Eguchi

Jichi Medical University School of Medicine Division of Cardiovascular Medicine, Departmentof Medicine

ke112@jichi.ac.jp0285-58-7344

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026